Australian vaccine preventable disease epidemiological review series: tetanus 2003–2019

Authors

  • Eliora SG Morris Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia
  • Aditi Dey Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia; National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia
  • Kaitlyn Vette Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia
  • Harunor Rashid Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia; National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia
  • Nicholas Wood Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia; National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia
  • Frank Beard Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia; National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia

DOI:

https://doi.org/10.33321/cdi.2023.47.61

Keywords:

booster vaccination, epidemiology, immunisation, tetanus, vaccine preventable disease

Abstract

Background

We examined trends in tetanus notification, hospitalisation and death data from 2003–2019 to assess the impact of adult tetanus booster recommendations in Australia.

Methods

Tetanus notifications and deaths from the National Notifiable Diseases Surveillance System; hospitalisations from the Australian Institute of Health and Welfare National Hospital Morbidity Database; and deaths from the Australian Coordinating Registry were analysed by age group, sex, Aboriginal and Torres Strait Islander status and state/territory. Annual rates were calculated using Australian Bureau of Statistics mid-year estimated resident populations from 2003–2019 as denominators. To assess the impact of a recommended booster dose of reduced antigen content diphtheria–tetanus–acellular pertussis (dTpa) vaccine for adults aged ≥ 65 years, notification, hospitalisation and death rates of tetanus per 100,000 population were compared pre (2003–2012) and post (2013–2019) the recommendation’s introduction.

Results

There were 63 notifications of tetanus from 2003–2019 with an average annual incidence rate of 0.02/100,000. Similar to previous studies, the burden of tetanus in the Australian population continues to disproportionately affect the elderly, with those aged ≥ 65 years encompassing 63% (40/63) of notifications and 100% (11/11) of the deaths observed in this timeframe. Following the introduction of a recommendation for those aged ≥ 65 years to receive a dTpa booster, average annual notification and hospitalisation rates in those aged ≥ 65 years were significantly lower (notifications: 0.11/100,000 in 2003–2012 and 0.05/100,000 in 2013–2019, p = 0.01; hospitalisations: 0.24/100,000 in 2003–2012 and 0.10/100,000 in 2013–2019, p = 0.01]). The average annual death rate was similar in the two periods (0.002/100,000), although based on small numbers.

Conclusions

The findings of this analysis suggest a positive impact from the 2013 recommendation. However, the burden is still disproportionately higher in those aged ≥ 65 years and strategies to improve vaccination coverage in older Australians are recommended.

Downloads

Download data is not yet available.

References

Farrar JJ, Yen LM, Cook T, Fairweather N, Binh N, Parry J et al. Tetanus. J Neurol Neurosurg Psychiatry. 2000;69(3):292–301. doi: https://doi.org/10.1136/jnnp.69.3.292.

Yen LM, Thwaites CL. Tetanus. Lancet. 2019;393(10181):1657–68. doi: https://doi.org/10.1016/s0140-6736(18)33131-3.

Tiwari TSP, Moro PL, Acosta AM. Tetanus. In Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases (the ‘Pink Book’) (14th edition). Washington DC: Centers for Disease Control and Prevention, Public Health Foundation, 2021.

Thwaites CL, Beeching NJ, Newton CR. Maternal and neonatal tetanus. Lancet. 2015;385(9965):362–70. doi: https://doi.org/10.1016/s0140-6736(14)60236-1.

Australian Government Department of Health and Aged Care. Australian Immunisation Handbook. [Website.] Canberra: Australian Government Department of Health and Aged Care, Australian Technical Advisory Group on Immunisation (ATAGI); 2022. Available from: https://immunisationhandbook.health.gov.au/.

National Centre for Immunisation Research and Surveillance (NCIRS). Significant events in diphtheria, tetanus and pertussis vaccination practice in Australia. Sydney: NCIRS; July 2018. [Accessed on 27 July 2021.] Available from: https://www.ncirs.org.au/sites/default/files/2018-11/Diphtheria-tetanus-pertussis-history-July-2018.pdf.

Quinn HE, McIntyre PB. Tetanus in the elderly--an important preventable disease in Australia. Vaccine. 2007;25(7):1304–9. doi: https://doi.org/10.1016/j.vaccine.2006.09.084.

Lu X, Quinn HE, Menzies RI, Hueston L, McIntyre PB et al. Tetanus immunity and epidemiology in Australia, 1993–2010. Infect Disord Drug Targets. 2020;20(3):330–40. doi: https://doi.org/10.2174/1871526518666181005111405.

Australian Government Department of Health and Aged Care. Tetanus – Surveillance case definition. [Webpage.] Canberra: Australian Government Department of Health and Aged Care; 1 July 2016. [Accessed on 27 June 2021.] Available from: https://www.health.gov.au/resources/publications/tetanus-surveillance-case-definition.

Juul S, Frydenberg M, Hansen S. EpiBasic. [Computer program.] Aarhus: The University of Aarhus; August 2019. Available from: https://ph.medarbejdere.au.dk/undervisning/software.

Collins S, Amirthalingam G, Beeching NJ, Chand MA, Godbole G, Ramsay ME et al. Current epidemiology of tetanus in England, 2001–2014. Epidemiol Infect. 2016;144(16):3343–53. doi: https://doi.org/10.1017/s095026881600128x.

Centers for Disease Control and Prevention. Tetanus surveillance --- United States, 2001–2008. MMWR Morb Mortal Wkly Rep. 2011;60(12):365–9.

Salem N, Huang G, Squires SG, Salvadori MI, Li YA. Epidemiology of tetanus in Canada, 1995–2019. Can J Public Health. 2023;114(3):432–40. doi: https://doi.org/10.17269/s41997-022-00732-7.

European Centre for Disease Prevention and Control (ECDC). Tetanus – annual epidemiological report for 2018. Solna: ECDC; 3 December 2020. Available from: https://www.ecdc.europa.eu/en/publications-data/tetanus-annual-epidemiological-report-2018.

ECDC. Tetanus – annual epidemiological report for 2017. Solna: ECDC; 28 June 2019. Available from: https://www.ecdc.europa.eu/en/publications-data/tetanus-annual-epidemiological-report-2017.

ECDC. Tetanus – annual epidemiological report for 2016. Solna: ECDC; 29 August 2018. Available from: https://www.ecdc.europa.eu/en/publications-data/tetanus-annual-epidemiological-report-2016.

ECDC. Tetanus – annual epidemiological report for 2015. Solna: ECDC; 29 November 2017. Available from: https://www.ecdc.europa.eu/en/publications-data/tetanus-annual-epidemiological-report-2015.

ECDC. Tetanus – annual epidemiological report 2016 [2014 data]. Solna: ECDC; 19 September 2016. Available from: https://www.ecdc.europa.eu/en/publications-data/tetanus-annual-epidemiological-report-2016-2014-data.

Parliament of Australia. House of Representatives Official Hansard. Thirty-eighth parliament first session—third period. No. 211, 1997. [Hansard.] Canberra: Parliament of Australia, House of Representatives Official Hansard; Tuesday, 25 February 1997; pp. 1163–84.

Australian Institute of Health and Welfare (AIHW). Tetanus in Australia. Canberra: Australian Government, AIHW; 13 November 2018. Available from: https://www.aihw.gov.au/getmedia/f877a2da-23e3-4516-948f-df05ca7ceb43/aihw-phe-236_Tetanus.pdf.aspx.

NCIRS. Significant events in immunisation policy and practice in Australia. Sydney: NCIRS; July 2020. [Accessed on 2 February 2023.] Available from: https://ncirs.org.au/sites/default/files/2020-07/Immunisation-policy-and-practice-Australia-1%20July%202020_Final%20for%20web.pdf.

Hull B, Deeks S, Menzies R, McIntyre P. Immunisation coverage annual report, 2007. Commun Dis Intell Q Rep. 2009;33(2):170–87.

Hull B, Hendry A, Dey A, Macartney K, Beard F. Immunisation Coverage Annual Report 2019. Commun Dis Intell (2018). 2021;45. doi: https://doi.org/10.33321/cdi.2021.45.18 10.33321/cdi.2020.45.18.

Hull B, Hendry A, Dey A, Brotherton J, Macartney K, Beard F. Annual immunisation coverage report 2020. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.60.

Liang JL, Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2018;67(2):1–44. doi: https://doi.org/10.15585/mmwr.rr6702a1.

Wagner KS, White JM, Andrews NJ, Borrow R, Stanford E, Newton E et al. Immunity to tetanus and diphtheria in the UK in 2009. Vaccine. 2012;30(49):7111–7. doi: https://doi.org/10.1016/j.vaccine.2012.09.029.

Steens A, Mollema L, Berbers GAM, van Gageldonk PGM, van der Klis FR, de Melker HE. High tetanus antitoxin antibody concentrations in the Netherlands: a seroepidemiological study. Vaccine. 2010;28(49):7803–9. doi: https://doi.org/10.1016/j.vaccine.2010.09.036.

Weir R, Jennings L, Young S, Brunton C, Murdoch D. National serosurvey of vaccine preventable diseases. Report to the Ministry of Health. Wellington: New Zealand Government Ministry of Health (Manatū Hauora); 2 May 2009. Available from: https://www.health.govt.nz/publication/national-serosurvey-vaccine-preventable-diseases.

Pillsbury A, Quinn HE, McIntyre PB. Australian vaccine preventable disease epidemiological review series: pertussis, 2006–2012. Commun Dis Intell Q Rep. 2014;38(3):E179–94.

Roper MH, Wassilak SGF, Scobie HM, Ridpath AD, Orenstein WA. 58 – Tetanus toxoid. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;1052–79.e18. doi: https//doi.org/10.1016/B978-0-323-35761-6.00058-4.

Hung MC, Williams WW, Lu PJ, Woods LO, Koppaka R, Lindley MC. Vaccination coverage among adults in the United States, National Health Interview Survey, 2017. [Webpage.] Atlanta: United States Government, Centers for Disease Control and Prevention; 8 February 2018. Available from: https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2017.html#.

Hammarlund E, Thomas A, Poore EA, Amanna IJ, Rynko AE, Mori M et al. Durability of vaccine-induced immunity against tetanus and diphtheria toxins: a cross-sectional analysis. Clin Infect Dis. 2016;62(9):1111–18. doi: https://doi.org/10.1093/cid/ciw066.

Gardner P. Issues related to the decennial tetanus-diphtheria toxoid booster recommendations in adults. Infect Dis Clin North Am. 2001;15(1):143–53. doi: https://doi.org/10.1016/s0891-5520(05)70272-5.

World Health Organization. Tetanus vaccines: WHO position paper – February 2017. Wkly Epidemiol Rec. 2017;92(6):53–76.

Havers FP, Moro PL, Hunter P, Hariri S, Bernstein H. Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the Advisory Committee on Immunization Practices — United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69:77–83. doi: https://doi.org/10.15585/mmwr.mm6903a5.

UK Health Security Agency. Tetanus: The Green Book, Chapter 30. London: Government of the United Kingdom, UK Health Security Agency; 1 June 2022. Available from: https://www.gov.uk/government/publications/tetanus-the-green-book-chapter-30.

Slifka AM, Park B, Gao L, Slifka MK. Incidence of tetanus and diphtheria in relation to adult vaccination schedules. Clin Infect Dis. 2020;72(2):285–92. doi: https://doi.org/10.1093/cid/ciaa017.

Downloads

Published

19/10/23

How to Cite

Morris, Eliora SG, Aditi Dey, Kaitlyn Vette, Harunor Rashid, Nicholas Wood, and Frank Beard. 2023. “Australian Vaccine Preventable Disease Epidemiological Review Series: Tetanus 2003–2019”. Communicable Diseases Intelligence 47 (October). https://doi.org/10.33321/cdi.2023.47.61.

Issue

Vol. 47 (2023)

Section

Original article

License

Copyright (c) 2023 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>